CLEMENT PHARMA
La probabilité de faillite calculée de CLEMENT PHARMA sur 12 mois est de 0,4% (très faible). L'entreprise est active depuis 1982 et le Moniteur belge ne contient aucun signal d'insolvabilité ou d'avertissement. Aucun chiffre de comptes annuels traité n'est disponible ; cette conclusion repose uniquement sur les données du registre et du Moniteur belge.
| Active | 43 ans |
| Sites | 1 |
| Publications | 2 |
Estimation statistique fondée sur des sources publiques — pas un conseil de crédit ni une constatation. Comment calculons-nous cela ?
| Exercice | Type | Dépôt | Référence |
|---|---|---|---|
| 31-12-2024 | verkort | 16-07-2025 | 2025-00280431 |
| 31-12-2023 | verkort | 24-07-2024 | 2024-00283265 |
| 31-12-2022 | verkort | 30-05-2023 | 2023-00098213 |
| 31-12-2021 | verkort | 27-06-2022 | 2022-20146231 |
| 31-12-2020 | verkort | 23-07-2021 | 2021-39200176 |
| 31-12-2019 | verkort | 24-06-2020 | 2020-20000231 |
| 31-12-2018 | verkort | 16-07-2019 | 2019-33500407 |
| 31-12-2017 | verkort | 20-07-2018 | 2018-36400549 |
| 31-12-2016 | verkort | 26-06-2017 | 2017-21600077 |
| 31-12-2015 | volledig | 30-05-2016 | 2016-14000282 |
| NACE primaire | 31001 |
| Forme juridique | SA(014) |
| Date de constitution | 23-12-1982 |
| Status | Actif |
| Code postal | 8870 |
Parcelles liées à cette entreprise via ses adresses BCE (siège, unités d'établissement, succursales), croisées avec le plan parcellaire cadastral. Ceci montre où l'entreprise est active — pas un registre de propriété.
| Parcelle (capakey) | Région | Superficie | Bâtiments | Hauteur / ét. |
|---|---|---|---|---|
| 36492A0306/00R002 | Flandre | 1,1 ha | 1 · 1,9 ha | 9,0 m · 2 ét. |
Une seule chronologie de tout ce qui est arrivé à cette entreprise — publications, événements d'insolvabilité et de cycle de vie, changements administratifs et comptes annuels déposés.
15-09-2025 2 administrateurs nommés
- Vandecappelle Els — Bestuurder
- Clement Jan — Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Vandecappelle Els",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "additional",
"via_org": {
"kbo": "0895.262.884",
"name": "4CC BV",
"address": "Kachtemsestraat 56/3, 8870 Izegem (Kachtem)",
"country": "BE",
"legal_form": "BV"
},
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "De algemene vergadering wenst over te gaan tot de benoeming van een bijkomende bestuurder.",
"decharge_status": null,
"mandate_duration": {
"kind": "until_agm_year",
"value": "2031"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Clement Jan",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "additional",
"via_org": {
"kbo": null,
"name": "4 GC SARL",
"address": "Boulevard Royal 25/A, 2449 Luxemburg",
"country": "LU",
"legal_form": "SARL"
},
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "Vervolgens besluit de vergadering te benoemen als bestuurder voor een periode ingaand op heden en eindigend onmiddellijk na de jaarvergadering van 2031: -4 GC SARL naar Luxemburgs recht, met zetel te Boulevard Royal 25/A, 2449 Luxemburg, Luxemburg",
"decharge_status": null,
"mandate_duration": {
"kind": "until_agm_year",
"value": "2031"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Els VANDECAPPELLE",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": {
"kbo": null,
"name": "BV \u00224CC\u0022",
"address": null,
"country": null,
"legal_form": "BV"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "Een gedelegeerd bestuurder BV \u00224CC\u0022 vertegenwoordigd door Els VANDECAPPELLE vaste.vertegenwoordiger.",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Gent",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2025-09-15",
"filing_date": "2025-09-05",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2025-06-28",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0423.344.820",
"name_full": "CLEMENT PHARMA",
"legal_form": "NV",
"_kbo_filled_from_list": true
},
"publication_proxy": {
"kind": null,
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"corrected_publication_numac": null
}05-10-2023 Toutes les parts sont désormais réunies entre les mains d'un seul actionnaire
Détails techniques
{
"events": [
{
"kind": "eenhoofdigheid_declaration",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": "reserves_incorporation",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
},
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_buyback",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": "inkoop_eigen_aandelen",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "agio_incorporation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": "kapitalisering_reserves",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "withdrawal_redemption",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "merger_share_issue",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_split",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "loss_absorption_only",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": "reserves_incorporation",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
},
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_buyback",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": "inkoop_eigen_aandelen",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "agio_incorporation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": "kapitalisering_reserves",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "withdrawal_redemption",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "merger_share_issue",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_split",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "loss_absorption_only",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Andreas LAGA",
"firm_city": null,
"firm_name": null,
"office_city": "Izegem",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2023-10-05",
"filing_date": "2023-10-03",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2023-09-18",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0423.344.820",
"name_full": "CLEMENT PHARMA",
"legal_form": "Naamloze vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"geco\u00F6rdineerde statuten met lijst publicatiedata"
],
"shareholders_after": [],
"share_classes_after": []
}Générez une note structurée et factuelle à partir de tous les signaux de ce dossier : risque, santé financière, structure de propriété, mandats et comparaison sectorielle.
| Dénomination légaleNL | CLEMENT PHARMA |